Inclusion Criteria:

Healthy biological females, between 18 and 45 years of age:

• SR surgery performed
• Body Mass Index (BMI) between 20 and 29 kg/m²; (body weight in kilograms divided by body height in meters squared)
• Clinical examination without pathological findings relevant to the study
• Clinico-chemical laboratory values do not suggest an illness
• Written Consent Form has been signed
• High probability of a good compliance and termination of the study

Exclusion Criteria:

Subjects cannot be enrolled in this study if one or more of the following criteria apply:

• Participation in another clinical trial within the 30 days preceding the first administration
• Simultaneous participation in another clinical trial
• Subjects institutionalized or imprisoned by order of the court
• Subject who compete in sports which use IOC drug monitoring
• Serious organic or psychic disease suspected from history and/or clinical examination
• Diseases (especially tumors) that might represent an actual contraindication for testosterone
• Past or present history of thrombotic or embolic diseases
• Hypertension requiring therapy (BP 140/90 mmHg)
• Diabetes mellitus requiring therapy
• Acute or chronic hepatic diseases
• Manifest renal diseases with renal dysfunction
• Severe internal diseases as well as use of any medication to treat such
• Biochemical and/or hematological laboratory values beyond normal ranges unless the Investigator confirms that the deviations are of no clinical relevance
• Any indication of chronic use of drugs, alcohol, opiates or recreational drugs
• Use of any drug known to affect biotransformation of testosterone and/or progestin, e.g. chlorcycline, phenobarbital, phenylbutazone, aminophenazone within the 30 days preceding the first administration of the test medication and during the study
• Use of oral anticoagulatory drugs within the 30 days preceding the first administration of the test medication and during the study
• Any oral or transdermal hormone medication within the 12 weeks preceding the first administration and during the study
• Probability of poor compliance and termination of the study